Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163722 | 1.00 | GCK (0.51) | GCKKDM4EALDH1A1CDK1GSK3A | |
| SCHEMBL2648770 | 1.00 | GCK (0.51) | GCKKDM4EALDH1A1CDK1GSK3A | |
| SCHEMBL6162187 | 0.85 | GCK (0.55) | GCK | |
| SCHEMBL6164423 | 0.85 | GCK (0.53) | GCK | |
| SCHEMBL2648408 | 0.85 | GCK (0.55) | GCK | |
| SCHEMBL2648783 | 0.85 | GCK (0.53) | GCK | |
| SCHEMBL6164904 | 0.85 | GCK (0.53) | GCK | |
| SCHEMBL2650438 | 0.85 | GCK (0.55) | GCK | |
| SCHEMBL2649995 | 0.82 | GCK (0.46) | GCK | |
| SCHEMBL6163804 | 0.82 | GCK (0.46) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280801-B1 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-07 | — | — | EP | claimed |
| US-6583288-B2 | (S,S)-2-((2-(4-(cyclohexyl)methyl-2,5-dioxoimidazolidin-1-yl)-3 -cyclopentylpropanoyl) amino)thiazole-4-carboxylic acid, methyl ester for example; for treatment of diabetes | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | claimed |
| EP-1280801-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | claimed |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | claimed |
| WO-2001083478-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | claimed |
| EP-1280801-B1 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-6784298-B2 | 2-((3-CYCLOHEXYL-2-(2,5-DIOXO-4-(THIOPHEN-2-YL)METHYLIMIDA-ZOL IDIN-1-YL)PROPANOYL)AMINO) THIAZOLE-4-CARBOXYLIC ACID METHYL ESTER, E.G.; ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS; A GLUCOSE SENSOR IN BETA-CELLS AND HEPATOCYTES | HOFFMANN-LA ROCHE INC. | 2004-08-31 | — | — | US | disclosed |
| US-20030225286-A1 | Hydantoin-containing glucokinase activators | GOODNOW ROBERT ALAN (US) | 2003-12-04 | — | — | US | disclosed |
| US-6583288-B2 | (S,S)-2-((2-(4-(cyclohexyl)methyl-2,5-dioxoimidazolidin-1-yl)-3 -cyclopentylpropanoyl) amino)thiazole-4-carboxylic acid, methyl ester for example; for treatment of diabetes | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1280801-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001083478-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225286-A1 | Hydantoin-containing glucokinase activators | GCK, GCKR, HK2 | GCK 1/4885KDM4E 3409/4885ALDH1A1 3307/4885 |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | GCK, GCKR, HK2 | GCK 1/4885KDM4E 3409/4885ALDH1A1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.